Lonza and Eclipse Therapeutics Announce Development and Manufacturing Agreement for Lonza to Conduct Phase 1 Production of Eclipse’s ET-101
Lonza will manufacture ET-101 at its mammalian development and manufacturing facility in Slough, UK
Lonza and Eclipse announced an agreement for the production of Eclipse’s novel cancer therapeutic antibody, ET-101, using Light Path™ Development Services. ET-101 is under investigation for the inhibition of the growth of cancer stem cells. Under the agreement, Lonza will produce phase 1 clinical material at its development and manufacturing facility in Slough, UK.
Cancer stem cells are a small subset of cells within a tumor that are thought to play a critical role in tumor initiation, recurrence and metastasis. ET-101 is a novel therapeutic antibody designed to target these cancer stem cells. Eliminating cancer stem cells, in conjunction with other therapies that address the tumor bulk, represents a new cancer treatment paradigm that could offer a distinct advantage over existing strategies and a solution for chemoresistance.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.